Lantheus Holdings (NASDAQ: LNTH), which makes diagnostic medical imaging agents that help physicians diagnose and treat cardiovascular and other diseases, saw its shares rise 16.4% on Friday. Lantheus also increased its full-year guidance to say it expects between $800 million and $835 million in revenue this year (up from a range of $685 million to $710 million) and full-year EPS between $2.90 and $3.15, up from a range of $1.95 to $2.05. The big driver for the company was the success of its prostate cancer imaging agent Plyarify and its FDA-approved artificial intelligence software program, Plyarify AI, that analyzes CT images to detect prostate cancer, which brought in $92.7 million in the first quarter.
前立腺シリーズではこっちの方がいいかもしれない、、
投資の参考になりましたか？
